6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one and 2-(4-amylcinnamoyl)amino-4-chlorobenzoic-acid

6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one has been researched along with 2-(4-amylcinnamoyl)amino-4-chlorobenzoic-acid* in 5 studies

Other Studies

5 other study(ies) available for 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one and 2-(4-amylcinnamoyl)amino-4-chlorobenzoic-acid

ArticleYear
Role of phospholipase A(2) in retrograde transport of ricin.
    Toxins, 2011, Volume: 3, Issue:9

    Ricin is a protein toxin classified as a bioterror agent, for which there are no known treatment options available after intoxication. It is composed of an enzymatically active A-chain connected by a disulfide bond to a cell binding B-chain. After internalization by endocytosis, ricin is transported retrogradely to the Golgi and ER, from where the ricin A-chain is translocated to the cytosol where it inhibits protein synthesis and thus induces cell death. We have identified cytoplasmic phospholipase A(2) (PLA(2)) as an important factor in ricin retrograde transport. Inhibition of PLA(2) protects against ricin challenge, however the toxin can still be endocytosed and transported to the Golgi. Interestingly, ricin transport from the Golgi to the ER is strongly impaired in response to PLA(2) inhibition. Confocal microscopy analysis shows that ricin is still colocalized with the trans-Golgi marker TGN46 in the presence of PLA(2) inhibitor, but less is colocalized with the cis-Golgi marker GM130. We propose that PLA(2) inhibition results in impaired ricin transport through the Golgi stack, thus preventing it from reaching the ER. Consequently, ricin cannot be translocated to the cytosol to exert its toxic action.

    Topics: Cell Line, Tumor; Chemical Warfare Agents; Chlorobenzoates; Cinnamates; Endocytosis; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; Naphthalenes; ortho-Aminobenzoates; Phospholipase A2 Inhibitors; Phospholipases A2; Protein Transport; Pyrones; Ricin; trans-Golgi Network

2011
A role for phospholipase A2 activity in membrane tubule formation and TGN trafficking.
    Traffic (Copenhagen, Denmark), 2010, Volume: 11, Issue:12

    We have investigated the role of phospholipase A(2) (PLA(2) ) enzymes in generating membrane tubules at the trans-Golgi network (TGN). Constitutive TGN membrane tubules and those induced by over-expressing kinase dead protein kinase D were inhibited by the PLA(2) inhibitors ONO-RS-082 (ONO) and bromoenol lactone. These antagonists also inhibited secretory delivery of both soluble and transmembrane cargoes. Finally, use of the reversible antagonist ONO and time-lapse imaging revealed for the first time that PLA(2) antagonists inhibit the initiation of membrane tubule formation at the TGN. Thus, PLA(2) enzymes appear to have an important role in the earliest steps of membrane tubule formation at the TGN, which are utilized for membrane trafficking.

    Topics: Aminobenzoates; Cell Line; Chlorobenzoates; Cinnamates; Group IV Phospholipases A2; Group VI Phospholipases A2; Humans; Naphthalenes; ortho-Aminobenzoates; Protein Transport; Proteins; Pyrones; trans-Golgi Network

2010
Arachidonyltrifluoromethy ketone, a phospholipase A(2) antagonist, induces dispersal of both Golgi stack- and trans Golgi network-resident proteins throughout the cytoplasm.
    Biochemical and biophysical research communications, 2001, Feb-23, Volume: 281, Issue:2

    Arachidonyltrifluoromethy ketone (AACOCF(3)), a phospholipase A(2) antagonist, reversibly induced dispersal of Golgi stack- and trans Golgi network (TGN)-resident proteins throughout the cytoplasm in NRK cells as followed by immunocytochemical staining of ManII and TGN38, respectively. The action of AACOCF(3) was partly blocked by other PLA(2) antagonists, suggesting it be not caused by a general inhibition of phospholipase A(2). AACOCF(3) neither dissociated beta-COP from membranes nor prevented brefeldin A-induced beta-COP release. Action of AACOCF(3) on the Golgi stack and TGN is different from that of brefeldin A and nordihydroguaiaretic acid. The most prominent difference is that the Golgi stack and TGN showed a similar sensitivity to AACOCF(3), while the TGN was dispersed more slowly than the Golgi stack in brefeldin A- or nordihydroguaiaretic acid-treated NRK cells. This novel action of AACOCF(3) may be used as pharmacological tool and give new insights into vesicle-mediated traffic and Golgi membrane dynamics.

    Topics: Aminobenzoates; Animals; Arachidonic Acids; Biological Transport; Brefeldin A; Cell Line; Chlorobenzoates; Cinnamates; Coatomer Protein; Cytoplasm; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Enzyme Inhibitors; Golgi Apparatus; Masoprocol; Membrane Proteins; Microscopy, Fluorescence; Naphthalenes; ortho-Aminobenzoates; Phospholipases A; Pyrones; Time Factors

2001
Calcium-independent phospholipase A(2) is required for human monocyte chemotaxis to monocyte chemoattractant protein 1.
    Journal of immunology (Baltimore, Md. : 1950), 2001, Sep-15, Volume: 167, Issue:6

    Monocyte chemoattractant protein 1 (MCP-1) has an important influence on monocyte migration into sites of inflammation. Our understanding of the signal transduction pathways involved in the response of monocytes to MCP-1 is quite limited yet potentially significant for understanding and manipulating the inflammatory response. Prior studies have demonstrated a crucial regulatory role for cytosolic phospholipase A(2) (cPLA(2)) in monocyte chemotaxis to MCP-1. In these studies we investigated the role for another PLA(2), calcium-independent PLA(2) (iPLA(2)) in comparison to cPLA(2). Pharmacological inhibitors of PLA(2) were found to substantially inhibit chemotaxis. Using antisense oligodeoxyribonucleotide treatment we found that iPLA(2) expression is required for monocyte migration to MCP-1. Complete blocking of the chemotactic response was observed with inhibition of either iPLA(2) or cPLA(2) expression by their respective antisense oligodeoxyribonucleotide. In reconstitution experiments, lysophosphatidic acid completely restored MCP-1-stimulated migration in iPLA(2)-deficient monocytes, whereas lysophosphatidic acid was without effect in restoring migration in cPLA(2)-deficient monocytes. To the contrary, arachidonic acid fully restored migration of cPLA(2)-deficient monocytes while having no effect on the iPLA(2)-deficient monocytes. Additional studies revealed that neither enzyme appears to be upstream of the other indicating that iPLA(2) and cPLA(2) represent parallel regulatory pathways. These data demonstrate novel and distinct roles for these two phospholipases in this critical step in inflammation.

    Topics: Aminobenzoates; Arachidonic Acid; Arachidonic Acids; Aristolochic Acids; Chemokine CCL2; Chemotaxis, Leukocyte; Chlorobenzoates; Cinnamates; Enzyme Inhibitors; Fatty Acids; Group IV Phospholipases A2; Group VI Phospholipases A2; Humans; Inflammation; Lysophospholipids; Monocytes; Naphthalenes; Oligodeoxyribonucleotides, Antisense; ortho-Aminobenzoates; Phenanthrenes; Phospholipases A; Pyrones; Signal Transduction

2001
Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2.
    Circulation research, 1996, Volume: 78, Issue:5

    [Arg8]-vasopressin (AVP) is both a potent vasoconstrictor and a mitogen for vascular smooth muscle cells. AVP binds to a single class of receptors (V1a) in the A7r5 rat aortic smooth muscle cell line (Kd approximately 2 nmol/L). Stimulation of these cells with AVP results in an increase in cytoplasmic free Ca2+ concentration ([Ca2+]i) by releasing intracellular Ca2+ stores and increasing Ca2+ influx; the EC50 for these effects is approximately 5 nmol/L. AVP has recently been reported to stimulate arachidonic acid release in primary cultures of rat aortic smooth muscle over a much lower concentration range (EC50 approximately 0.05 nmol/L). The present study examined the effects of varying concentrations of AVP on spontaneous Ca2+ spiking activity in fura 2-loaded A7r5 cells. Frequency of CA2+ spiking increased with increasing [AVP] in the range of 10 to 500 pmol/L. Higher concentrations of AVP inhibited spiking but elicited the characteristic [Ca2+]i changes ascribed to the release of Ca2+ stores and increased Ca2+ entry. The effects of both low and high concentrations of AVP were inhibited by [1-(beta-mercapto-beta,beta,-pentamethylenepropionic acid),2-0-methyltyrosine]arginine vasopressin, a selective V1a vasopressin antagonist. Nimodipine (50 nmol/L), a blocker of L-type voltage-sensitive Ca2+ channels, abolished the Ca(2+)-spiking activity without inhibiting a maximal [Ca2+]i response to AVP (1 mumol/L). AVP-stimulated Ca2+ spiking, but not release of intracellular Ca2+ stores, was also abolished by ONO-RS-082 (1 mumol/L), an inhibitor of phospholipase A2. These results suggest that occupation of a small fraction of V1a vasopressin receptors by AVP results in stimulation of phospholipase A2 and leads to increased Ca(2+)-spiking activity. This effect may be important for fine tuning of vascular tone, whereas maximal stimulation by AVP (full receptor occupancy) may be required for more vigorous or sustained vasoconstriction or mitogenesis.

    Topics: Aminobenzoates; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Calcium; Cell Line; Chlorobenzoates; Cinnamates; Electrophysiology; Enzyme Activation; Muscle, Smooth, Vascular; Naphthalenes; ortho-Aminobenzoates; Osmolar Concentration; Phospholipases A; Phospholipases A2; Pyrones; Rats

1996